Abstract: Body-mountable devices are provided to detect the presence or status of a tumor in a body by detecting probes associated with circulating cells of the tumor that travel to subsurface vasculature of the body. The probe enters a tumor and associates with cells of the tumor before the cells metastasize. A wearable body-mountable device can be worn for a protracted period of time to detect the probe associated with circulating tumor cells in the vasculature at low concentrations and/or at low rates. A body-mounted device could detect the presence of such released, tumor-cell-associated probes to determine a presence or status of a tumor in the body.

Abstract: A method for profiling extracellular vesicles (EV) is provided.

Abstract: Body-mountable devices are provided to detect the presence or status of a tumor in a body by detecting one or more properties of a probe located in subsurface vasculature of the body. A wearable body-mountable device can be worn for a protracted period of time to detect a probe in the vasculature at low concentrations and/or at low rates. A body-mountable device can detect properties of the probe that are indicative of whether the probe has interacted with a tumor of the body and determine the presence or status of a tumor in the body based on such detected properties. Additionally or alternatively, the probe could be introduced into the body as a probe aggregate and released from if the probe aggregate is absorbed by a tumor. The presence of released probes could be detected to determine a presence or status of a tumor in the body.

Abstract: A system is provided which includes nanoparticle conjugates configured to bind with a tumor cell, the nanoparticle conjugate comprising a nanoparticle, at least one targeting entity bound to the nanoparticle, and at least one shielding entity that shields at the at least one targeting entity, the nanoparticle, or both; a body-mountable device mounted on an external surface of a living body and configured to detect a tumor cell binding response signal transmitted through the external surface, wherein the tumor cell binding response signal is related to binding of the nanoparticle conjugates with one or more tumor cells; and a processor configured to non-invasively detect the one or more tumor cells based on the tumor cell response signal. Nanoparticle conjugates and methods for use for treating or imaging tumor cells are also provided.

Abstract: The present invention relates generally to the fields of cell biology and laboratory diagnostics, and particularly to general compositions and of uniquely tagged particles linked to moieties of known properties and methods of making tagged, functionalized particles. Additionally, the invention relates to methods of screening a collection of tagged functionalized particles.

Abstract: A system is provided which includes nanoparticle conjugates configured to bind with a tumor cell, the nanoparticle conjugate comprising a nanoparticle, at least one targeting entity bound to the nanoparticle, and at least one shielding entity that shields at the at least one targeting entity, the nanoparticle, or both; a body-mountable device mounted on an external surface of a living body and configured to detect a tumor cell binding response signal transmitted through the external surface, wherein the tumor cell binding response signal is related to binding of the nanoparticle conjugates with one or more tumor cells; and a processor configured to non-invasively detect the one or more tumor cells based on the tumor cell response signal. Nanoparticle conjugates and methods for use for treating or imaging tumor cells are also provided.

Abstract: The present invention relates generally to the fields of cell biology and laboratory diagnostics, and particularly to general compositions and of uniquely tagged particles linked to moieties of known properties and methods of making tagged, functionalized particles. Additionally, the invention relates to methods of screening a collection of tagged functionalized particles.

Abstract: A nanoparticle conjugate includes a nanoparticle, first oligonucleotides of one or more types bound to the nanoparticle, each type of first oligonucleotide having a sequence, and targeting conjugates of one or more types, each type of targeting conjugate comprising a targeting entity and a second oligonucleotide bound to the targeting entity and having a sequence that is complementary to a sequence of a predetermined type of the first oligonucleotides, wherein the second oligonucleotide are covalently bound to a surface of the nanoparticle, a functional group on the surface of the nanoparticle, or one of the first oligonucleotide. Also provided are methods for making such nanoparticle conjugates and methods and devices for using such nanoparticle conjugates.

Abstract: Methods for characterizing a cell employ a library of nanoparticle conjugates of one or more types, each type of nanoparticle conjugate comprising a nanoparticle, targeting entities of one or more types, and tags of one or more types, to determine the genotype and phenotype of a cell as well as other characteristics. The tags can include oligonucleotide barcodes.

Abstract: A system is provided which includes nanoparticle conjugates configured to bind with a tumor cell, the nanoparticle conjugate comprising a nanoparticle, at least one targeting entity bound to the nanoparticle, and at least one shielding entity that shields at the at least one targeting entity, the nanoparticle, or both; a body-mountable device mounted on an external surface of a living body and configured to detect a tumor cell binding response signal transmitted through the external surface, wherein the tumor cell binding response signal is related to binding of the nanoparticle conjugates with one or more tumor cells; and a processor configured to non-invasively detect the one or more tumor cells based on the tumor cell response signal. Nanoparticle conjugates and methods for use for treating or imaging tumor cells are also provided.

Abstract: A method for identifying a compound expected to be useful in modulating a WNK (With No Lysine Kinase) isoform protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates the protein kinase activity of a WNK isoform polypeptide on the substrate SPAK (STE20/SPS1-related Proline-Alanine-rich Kinase) or OSR1 (Oxidative Stress Response kinase-1) and (2) selecting a compound which modulates the said WNK isoform polypeptide protein kinase activity. Such a compound may be useful as an antihypertensive agent or for the treatment of, for example, Gordon's syndrome.